MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $2.80B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $20.1K in total
- 1
- 13F holdersQ2 2026, +17 vs. previous quarter
- 172
- 13F valueReported value at the end of Q2 2026
- $3.06B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$87.0M
- No comparable prior period
- Free cash flow, FY2025
- -$81.9M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.29M
- Shares sold short
- Change
- −137.7K
- −3.1% vs. previous
- Days to cover
- 7.90
- At average daily volume
Superinvestors holding MBX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MBX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by MBX Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)4:10 PM ET | Nov 4 | 1 day | Azoulay SalomonChief Medical Officer | SSale | −373 | $53.96 | −$20.1K | −2.6%14.0K after | |
| Aug 5, 2026 (view filing)4:57 PM ET | Aug 4 | 1 day | Azoulay SalomonChief Medical Officer | SSale | −370 | $65.77 | −$24.3K | −2.5%14.4K after | |
| May 11, 2026 (view filing) | May 8 | 3 days | Azoulay SalomonChief Medical Officer | SSale | −70.0K | $38.36 | −$2.69M | −82.6%14.8K after | 2 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Azoulay SalomonChief Medical Officer | SSale | −231 | $29.54 | −$6.82K | −1.5%14.8K after | |
| May 8, 2026 (view filing) | May 6 | 2 days | Hawryluk P. KentPresident & CEO | SSale | −607 | $29.54 | −$17.9K | −0.1%727.7K after | |
| Mar 16, 2026 (view filing) | Mar 13 | 3 days | Hawryluk P. KentPresident & CEO | PPurchase | +18.5K | $28.41 | +$525.6K | +4.0%486.8K after | |
| Oct 21, 2025 (view filing) | Oct 20 | 1 day | Hawryluk P. KentPresident & CEO | PPurchase | +20.0K | $13.64 | +$272.8K | +4.5%468.3K after | |
| Oct 20, 2025 (view filing) | Oct 17 | 3 days | Hoerter Steven L.Director | PPurchase | +20.0K | $13.25 | +$265.0K | New position20.0K after | |
| Sep 30, 2025 (view filing)4:59 PM ET | Sep 26 | 4 days | Heron Patrick J and 4 othersDirector, 10% Owner | PPurchase | +666.7K | $18.00 | +$12.0M | +14.6%5.22M after | |
| Apr 10, 2025 (view filing) | Apr 8 | 2 days | Pescovitz Ora H.Director | PPurchase | +7.69K | $5.89 | +$45.3K | +46.2%24.3K after |
Top 10 13F holders, Q2 2026
See all 172 holdersThe largest institutional positions in MBX Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,652,013 | $367.2M | 8.00% | 00.0% | Unchanged |
| FMR LLC | 5,322,885 | $293.8M | 0.01% | +2,386,201+81.3% | Added |
| Wellington Management Group LLP | 4,977,523 | $274.8M | 0.05% | +1,785,699+55.9% | Added |
| NEA Management Company, LLC | 3,614,486 | $199.5M | 12.56% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,428,736 | $189.3M | 3.58% | −209,151−5.7% | Reduced |
| BlackRock, Inc. | 3,323,672 | $183.5M | 0.00% | +382,266+13.0% | Added |
| Paradigm Biocapital Advisors LP | 2,508,015 | $138.4M | 2.59% | +2,508,015 | New |
| NVP Associates, LLC | 2,136,335 | $117.9M | 35.93% | 00.0% | Unchanged |
| Deep Track Capital, LP | 1,732,569 | $95.6M | 1.41% | −1,025,000−37.2% | Reduced |
| Polar Capital Holdings Plc | 1,608,514 | $88.8M | 0.25% | −13,672−0.8% | Reduced |
Holders of 5% or more of MBX
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of MBX Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%7.22M shares | +3.80 ppfrom 11.20% | May 6, 20263 filings | Nov 5, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13D/A | 11.70%5.24M shares | 0.00 ppfrom 11.70% | Sep 23, 20244 filings | Aug 10, 2026 | SEC |
| Wellington Management Group LLP | 13G/A | 10.50%4.98M shares | +3.00 ppfrom 7.50% | Nov 8, 20246 filings | Jul 8, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D/A | 8.10%3.62M shares | – | Sep 23, 20242 filings | Nov 10, 2025 | SEC |
| OrbiMed Advisors LLC | 13D/A | 6.40%3.07M shares | −1.30 ppfrom 7.70% | Sep 23, 20244 filings | Aug 10, 2026 | SEC |